– Company intends to move forward with a single, Phase 1/2/3 trial in dopamine transporter deficiency syndrome (DTDS) –   London, UK, 26 April 2023 – Bloomsbury Genetic Therapies Limited, a clinical-stage biotechnology company developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases based on clinically proven gene therapy technologies, today […]

– ODD granted in the United States and the European Union –   London, UK, 26 January 2023 – Bloomsbury Genetic Therapies Limited (Bloomsbury), a clinical-stage biotechnology company developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases based on clinically proven gene therapy technologies, today announced that both the United States […]

London, UK, 10 October 2022 – Bloomsbury Genetic Therapies Limited (“Bloomsbury”), a biotechnology company developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases, based on clinically proven gene therapy technologies, today announced that pre-clinical data from two of its brain-targeted programs, BGT-INAD and BGT-DTDS, will be featured respectively in an oral […]